Semaglutide vs tirzepatide: the real head-to-head comparison

Semaglutide vs tirzepatide is the most-searched comparison in metabolic medicine right now. Until 2025, the answer lived in cross-trial comparison. Then the NEJM published a direct head-to-head trial — and the pharmacology finally matched the indirect data. Tirzepatide produces more weight loss. The question worth asking is which drug is right for a given person, not which is universally better.

The head-to-head trial that settled the efficacy question#

For years, the semaglutide vs tirzepatide debate relied on indirect comparison: look at STEP 1 (semaglutide 14.9%) and SURMOUNT-1 (tirzepatide 22.5%), do the math on similar populations, conclude tirzepatide has a ~50% larger effect. The problem with indirect comparison is that patient populations, trial protocols, and endpoints differ enough that numbers aren't perfectly comparable.

The SURMOUNT-5 trial, published in NEJM in 2025, eliminated that uncertainty. It directly randomised adults with obesity to tirzepatide (up to 15 mg weekly) or semaglutide (up to 2.4 mg weekly) at their highest approved doses, and measured body weight at 72 weeks.

Results at 72 weeks:

• Tirzepatide: −20.2% mean body weight
• Semaglutide: −13.7% mean body weight
• Absolute difference: 6.5 percentage points
• Waist circumference: −18.4 cm (tirzepatide) vs −13.0 cm (semaglutide)

The tirzepatide advantage is real, statistically significant, and clinically meaningful. For a 100-kg starting weight, that's 20.2 kg vs 13.7 kg — a 6.5 kg absolute difference, or approximately 14 pounds.

The mechanism explanation#

The difference is pharmacology, not chance.

Semaglutide is a GLP-1 receptor agonist. It activates one incretin pathway — the GLP-1 receptor — which suppresses appetite, slows gastric emptying, and stimulates insulin release during meals.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates GLP-1 and adds the second major incretin receptor (GIP). GIP has its own effects on insulin secretion and adipose tissue, and the combination with GLP-1 appears to produce synergistic weight loss that neither pathway achieves alone.

This isn't a surprise in retrospect. Preclinical models of dual-agonism predicted tirzepatide would outperform single-agonism by a meaningful margin. The head-to-head trial confirmed the prediction. For the full class mechanism, see the GLP-1 class explained.

The safety and side-effect comparison#

The side-effect profiles are strikingly similar. Both drugs are dominated by gastrointestinal events that concentrate during dose escalation:

Side effect	Semaglutide (~2.4 mg)	Tirzepatide (~15 mg)
Nausea	~44%	~29%
Diarrhoea	~30%	~23%
Vomiting	~24%	~13%
Constipation	~24%	~17%
Abdominal pain	~20%	~11%

Tirzepatide appears to have slightly lower GI side-effect rates at target dose than semaglutide, possibly because GIP activation partially offsets the GLP-1-driven gastric slowing. This is a secondary finding and not the headline from head-to-head data.

Discontinuation rates due to adverse events are similar: ~5–7% for both drugs in Phase 3 trials. Serious adverse event rates are comparable.

Both drugs carry the same absolute contraindication set:

• Personal or family history of medullary thyroid carcinoma or MEN 2
• Pregnancy or planned pregnancy
• History of pancreatitis (requires specialist input)
• Severe gastroparesis
• Type-1 diabetes

See who shouldn't take peptides for the full framework.

Where semaglutide has the stronger position#

Despite tirzepatide's efficacy advantage, semaglutide has two structural advantages worth weighing:

1. Established cardiovascular benefit. The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease. This is the first obesity drug with proven cardiovascular outcome benefit — a category that matters for insurance coverage, clinical guidelines, and long-term decision-making. Tirzepatide's equivalent cardiovascular outcomes trial (SURPASS-CVOT) is still enrolling as of April 2026.

2. Longer real-world track record. Semaglutide has been in widespread clinical use since 2017 for type-2 diabetes (Ozempic) and since 2021 for obesity (Wegovy). Tirzepatide is newer: approved 2022 (Mounjaro) and 2023 (Zepbound). More clinical use means more post-market safety data. Both drugs appear safe, but "more safety data" has value.

For a patient with cardiovascular disease, semaglutide remains the first-line choice based on outcome evidence. For a patient optimising for weight loss alone, tirzepatide has the clearer efficacy case.

The cost-effectiveness angle#

Published health-economic analyses put the cost per 1% of body weight reduction at roughly:

• Tirzepatide: ~$985 per 1% weight reduction
• Semaglutide: ~$1,845 per 1% weight reduction

Tirzepatide is nearly twice as cost-effective per percentage point despite being priced similarly per month — because it produces more weight loss for the same monthly spend. This matters particularly for out-of-pocket patients or private insurance with step-therapy rules.

Norwegian reimbursement rules apply similarly to both: type-2 diabetes is generally reimbursable under blue-resept; obesity-only indication is generally full out-of-pocket. Both drugs are approved by Legemiddelverket under their international brand names.

Retatrutide sits above both#

No discussion of semaglutide vs tirzepatide is complete without the retatrutide context. Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) that produced 28.7% mean weight loss at 68 weeks in Phase 3 TRIUMPH-4. It's not approved anywhere as of April 2026; expected approval 2027–2028.

The full class picture:

Drug	Receptors	Weight loss	Approval
Semaglutide	GLP-1	14.9%	Approved
Tirzepatide	GIP + GLP-1	22.5%	Approved
Retatrutide	GIP + GLP-1 + glucagon	28.7%	Not yet

For more on retatrutide, see the retatrutide guide.

How to think about the choice#

Five factors determine the right drug for a given person:

1. Primary goal. Weight-loss-focused: tirzepatide's efficacy case is stronger. Cardiovascular-risk-reduction-focused: semaglutide's outcome evidence is the category-defining trial.
2. Baseline disease. Established cardiovascular disease + obesity → semaglutide first (based on SELECT). Isolated obesity without cardiovascular disease → either, with tirzepatide's efficacy advantage as a tiebreaker.
3. Side-effect sensitivity. For patients who've had severe GI side effects on one class-drug previously, tirzepatide's slightly milder profile may matter.
4. Cost and coverage. Check Norwegian reimbursement rules and out-of-pocket pricing before choosing. Tirzepatide's cost-per-efficacy advantage may matter for out-of-pocket scenarios.
5. Long-term timeline. If retatrutide's expected 2027–2028 approval is on the horizon and the patient is research-use oriented, that's a factor in protocol planning.

For structured intake that filters across all of these, Syntho's questionnaire maps symptoms, contraindications, goals, and bloodwork against the approved-drug profile. The individual tirzepatide guide and semaglutide guide cover each drug in depth.

The semaglutide vs tirzepatide comparison has a clear winner on the headline efficacy metric. It has no universal winner on the actual clinical question. The right drug is the one that matches the individual — and the framework for choosing is more than a single number from a single trial.